Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Olanzapine Augmentation in Clozapine-resistant Schizophrenia: a Randomized Double-blind Study

NCT00918021 is registered in ClinicalTrials.gov with Niuvanniemi Hospital as lead sponsor.

NCT NCT00918021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00918021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Olanzapine Augmentation in Clozapine-resistant Schizophrenia: a Randomized Double-blind Study
Lead sponsor
Niuvanniemi Hospital
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2009
Completion date
July 31, 2010
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia